TY - JOUR
T1 - Economic Analysis and Long-term Follow-up of Distant Referral for Degenerative Mitral Valve Repair
AU - Michigan Mitral Research Group (MMRG)
AU - Brescia, Alexander A.
AU - Paulsen, Michael J.
AU - Watt, Tessa M.F.
AU - Rosenbloom, Liza M.
AU - Wisniewski, Alexander M.
AU - Li, Jun
AU - Wang, Guihua
AU - Likosky, Donald S.
AU - Hopp, Wallace J.
AU - Bolling, Steven F.
N1 - Publisher Copyright:
© 2021 The Society of Thoracic Surgeons
PY - 2021/2
Y1 - 2021/2
N2 - Background: Despite the superiority of mitral valve repair (MVr) over replacement for degenerative disease, repair rates vary widely across centers. Traveling to a mitral reference center (MRC) is 1 way to increase the odds of MVr. This study assessed the economic value (quality/cost) and long-term outcomes of distant referral to an MRC. Methods: Among 746 mitral surgery patients between January 2011 and June 2013, low-risk patients with an ejection fraction greater than 40% undergoing isolated degenerative MVr were identified and included 26 out-of-state (DISTANT) and 104 in-state patients (LOCAL). Short- and long-term outcomes and institutional financial data (including travel expenses) were used to compare groups. National average and MRC-specific MVr rates, clinical outcomes, and marginal value of quality-adjusted life-years collected from The Society of Thoracic Surgeons database and Medicare estimates were used to perform a nationally representative cost-benefit analysis for distant referral. Results: Age, ejection fraction, operative time, blood transfusions, and annuloplasty ring size did not differ between groups. Median charges were $76,022 for LOCAL and $74,171 for DISTANT (P =. 35), whereas median payments (including travel expenses) were $57,795 for LOCAL and $58,477 for DISTANT (P =. 70). Short- and long-term outcomes were similar between groups and median follow-up was 7.1 years. Estimated 5-year survival was 97% (96% for LOCAL and 100% for DISTANT; P =. 24). Cost-benefit analysis showed a net benefit through distant referral to an MRC ranging from $436 to $6078 to the payer and $22,163 to $30,067 to the patient, combining for an estimated $22,599 to $32,528 societal benefit. Conclusions: These data suggest that distant referral to an MRC is achievable and reasonable.
AB - Background: Despite the superiority of mitral valve repair (MVr) over replacement for degenerative disease, repair rates vary widely across centers. Traveling to a mitral reference center (MRC) is 1 way to increase the odds of MVr. This study assessed the economic value (quality/cost) and long-term outcomes of distant referral to an MRC. Methods: Among 746 mitral surgery patients between January 2011 and June 2013, low-risk patients with an ejection fraction greater than 40% undergoing isolated degenerative MVr were identified and included 26 out-of-state (DISTANT) and 104 in-state patients (LOCAL). Short- and long-term outcomes and institutional financial data (including travel expenses) were used to compare groups. National average and MRC-specific MVr rates, clinical outcomes, and marginal value of quality-adjusted life-years collected from The Society of Thoracic Surgeons database and Medicare estimates were used to perform a nationally representative cost-benefit analysis for distant referral. Results: Age, ejection fraction, operative time, blood transfusions, and annuloplasty ring size did not differ between groups. Median charges were $76,022 for LOCAL and $74,171 for DISTANT (P =. 35), whereas median payments (including travel expenses) were $57,795 for LOCAL and $58,477 for DISTANT (P =. 70). Short- and long-term outcomes were similar between groups and median follow-up was 7.1 years. Estimated 5-year survival was 97% (96% for LOCAL and 100% for DISTANT; P =. 24). Cost-benefit analysis showed a net benefit through distant referral to an MRC ranging from $436 to $6078 to the payer and $22,163 to $30,067 to the patient, combining for an estimated $22,599 to $32,528 societal benefit. Conclusions: These data suggest that distant referral to an MRC is achievable and reasonable.
UR - http://www.scopus.com/inward/record.url?scp=85098114814&partnerID=8YFLogxK
U2 - 10.1016/j.athoracsur.2020.05.114
DO - 10.1016/j.athoracsur.2020.05.114
M3 - Article
C2 - 32693045
AN - SCOPUS:85098114814
SN - 0003-4975
VL - 111
SP - 479
EP - 486
JO - Annals of Thoracic Surgery
JF - Annals of Thoracic Surgery
IS - 2
ER -